Retatrutide Complete Guide: Phase 3 Results, Dosing, Side Effects & FDA Status

Retatrutide is an investigational peptide developed by Eli Lilly & Company (internal designation LY3437943). It is not FDA-approved, not available by prescription, and not sold as a supplement. Outside of Lilly's authorized clinical trials, it is available only from research chemical suppliers for laboratory research purposes under a "not for human consumption" designation.

With that context clear: retatrutide has generated substantial scientific interest because it acts simultaneously on three metabolic hormone receptors — GLP-1, GIP, and glucagon — making it mechanistically distinct from any approved GLP-1 drug on the market. Phase 2 trial data reported some of the largest body weight reductions ever observed in an obesity pharmacology study (Jastreboff et al., NEJM 2023), and the first Phase 3 results — TRIUMPH-1 topline data — were reported by Eli Lilly in May 2026, with the broader TRIUMPH program still ongoing. This guide synthesizes what the trial literature reports about its mechanism, dosing, side effects, and current status.

Nothing in this guide constitutes medical advice or dosing instructions for human use.

Quick facts#

What is retatrutide?#

Retatrutide is a triple agonist — a single synthetic peptide molecule engineered to activate three distinct G protein-coupled receptors simultaneously:

• GLP-1R (glucagon-like peptide-1 receptor) — the same receptor targeted by semaglutide (Semaglutide) and Tirzepatide, among others. GLP-1R activation stimulates insulin secretion, suppresses glucagon in a glucose-dependent manner, slows gastric emptying, and reduces appetite.
• GIPR (glucose-dependent insulinotropic polypeptide receptor) — also targeted by tirzepatide. GIP receptor activation augments the insulin-stimulating effect of GLP-1, and GIP may influence tolerability, but this remains under investigation.
• GcgR (glucagon receptor) — not targeted by any currently approved GLP-1/GIP drug. Glucagon receptor activation is hypothesized to contribute to increased energy expenditure and hepatic fat metabolism, and may add weight-reduction effects beyond appetite suppression alone.

Because it engages all three receptors, retatrutide is sometimes referred to in research and community contexts as a "GLP-3" or "triple agonist" — though these are informal designations, not pharmacological classifications. The GLP-3 label distinguishes it from dual agonists (GLP-1/GIP, as with tirzepatide) and single agonists (GLP-1 only, as with semaglutide or liraglutide).

Retatrutide is a long-chain fatty acid-acylated peptide designed for once-weekly subcutaneous administration, similar in delivery format to tirzepatide and semaglutide. Its molecular structure incorporates modifications that extend its half-life in circulation — see the half-life section below.

How retatrutide works#

GLP-1 receptor arm#

The GLP-1 component of retatrutide suppresses appetite centrally (via hypothalamic and brainstem pathways), stimulates glucose-dependent insulin secretion from pancreatic beta cells, and slows gastric emptying — reducing caloric intake through both appetite and gastric mechanisms. This is the same pathway leveraged by all approved GLP-1 drugs.

GIP receptor arm#

The GIPR component potentiates the insulinotropic effect of GLP-1 at normal and elevated blood glucose. Research suggests GIPR agonism may also improve tolerability of GLP-1 effects — the combination may reduce the nausea burden compared to high-dose GLP-1 monotherapy, though this remains under investigation (Jastreboff et al., NEJM 2023). This is the same pairing used in tirzepatide.

Glucagon receptor arm#

The GcgR component is what mechanistically separates retatrutide from tirzepatide. Glucagon receptor activation is hypothesized to contribute to increased energy expenditure and hepatic fat metabolism — the liver oxidizing fat at a higher rate. In isolation, glucagon agonism raises blood glucose (the classic glucagon function in hypoglycemia rescue); in the context of simultaneous GLP-1R and GIPR agonism, the GLP-1/GIP arms may help offset glucagon's glucose-raising tendency, while the thermogenic and hepatic fat-metabolism effects are thought to persist (Jastreboff et al., NEJM 2023). This is the theoretical basis proposed for the greater weight-reduction signal observed with retatrutide versus dual agonists.

Half-life and dosing interval#

Retatrutide is engineered for a long circulating half-life via fatty acid acylation, enabling once-weekly subcutaneous dosing. Reported half-life from Phase 1 and Phase 2 data is approximately six days (Jastreboff et al., NEJM 2023), consistent with a once-weekly injection schedule and steady-state accumulation over several weeks.

Benefits and trial results#

Phase 3 TRIUMPH-1 topline results (2026)#

On May 21, 2026, Eli Lilly announced topline results from TRIUMPH-1, the first Phase 3 trial of retatrutide — conducted in adults with obesity or overweight (without type 2 diabetes) and at least one weight-related comorbidity. These are the first Phase 3 efficacy readouts for the compound, and they reinforced the magnitude seen in Phase 2 (Eli Lilly, May 21 2026).

Notably, 45.3% of participants on the 12 mg dose achieved at least a 30% reduction in body weight — a threshold previously associated mainly with bariatric surgery (Eli Lilly, May 21 2026). These are company-reported topline figures; the full peer-reviewed publication and the remaining TRIUMPH readouts (including the type 2 diabetes and cardiovascular-outcome arms) are still pending.

These are reported trial figures cited from Eli Lilly's topline announcement; they are outcomes under controlled clinical conditions, not guaranteed results and not applicable to research or personal use.

Phase 2 trial (NEJM, 2023)#

The Phase 2 obesity clinical trial of retatrutide (NCT04881760), published in the New England Journal of Medicine (Jastreboff et al., NEJM 2023), evaluated multiple weekly dose arms — including 1 mg, 4 mg, 8 mg, and 12 mg — against placebo in adults with obesity or overweight. The Phase 3 TRIUMPH program is a separate set of trials (covered below). Key findings from the Phase 2 trial:

• Lilly reported a mean body weight reduction of up to 17.5% from baseline at 24 weeks, with the strongest results in the higher-dose groups (Jastreboff et al., NEJM 2023).
• At 48 weeks, mean reduction reached up to 24.2% from baseline (Jastreboff et al., NEJM 2023) — again concentrated in the higher-dose groups, and among the largest sustained weight reductions reported in a pharmacological obesity trial at the time of publication.
• Improvements in metabolic markers — fasting blood glucose, insulin resistance, waist circumference, lipids — were observed across dose groups (Jastreboff et al., NEJM 2023).
• Glycemic benefit was observed in participants with and without type 2 diabetes.

Phase 2 trial results (adults with obesity/overweight):

These are reported trial figures cited from the published literature; they are not guaranteed outcomes and refer to results under controlled clinical conditions, not research or personal use.

Phase 3 trials (TRIUMPH program)#

Eli Lilly's TRIUMPH Phase 3 program is underway, and the first topline results have now been reported. TRIUMPH-1 (obesity, without T2D) delivered topline efficacy data in May 2026 — summarized in the Phase 3 TRIUMPH-1 topline results section above. The remaining trials — TRIUMPH-2 (obesity with T2D), type 2 diabetes, and cardiovascular outcomes (TRIUMPH-4 and related arms) — are ongoing. Peer-reviewed publication of the full TRIUMPH-1 dataset and the additional TRIUMPH readouts are still pending. Researchers following the program should refer to ClinicalTrials.gov (NCT listings) and Lilly's investor disclosures for updates.

Metabolic effects beyond weight#

Beyond body weight, Phase 2 data reported effects on:

• Hepatic steatosis — reduction in liver fat, consistent with the glucagon receptor mechanism (Jastreboff et al., NEJM 2023)
• Lipid panel improvements — reductions in triglycerides and improvements in HDL/LDL ratios (Jastreboff et al., NEJM 2023)
• Blood pressure — modest reductions in systolic blood pressure observed at higher doses (Jastreboff et al., NEJM 2023)
• Glycemic control — HbA1c and fasting glucose reductions in participants with T2D (Rosenstock et al., Lancet 2023)

All of the above are reported trial outcomes, not claims applicable to research use or personal use.

Dosing and titration schedule#

The following is based on the dose escalation schedule used in Phase 2 and Phase 3 clinical trials, as reported in published literature and public trial registrations. This is reported research protocol information only — it is not dosing guidance, a treatment protocol, or medical advice.

Phase 2 dose groups (reported)#

The Phase 2 obesity trial (NCT04881760) used multiple weekly dose arms — including 1 mg, 4 mg, 8 mg, and 12 mg — with a titration ramp to reach each target dose. The starting dose in the higher cohorts was lower and escalated over weeks (Jastreboff et al., NEJM 2023).

Phase 3 / TRIUMPH titration schedule (reported)#

The Phase 3 trials use a stepwise titration schedule designed to minimize GI side effects during the initiation period. As reported in trial registrations and the freemedicaljournals.com summary of the prescribing protocol, the reported schedule is:

• Weeks 1–4: 2 mg once weekly
• Weeks 5–8: 4 mg once weekly
• Weeks 9–12: 6 mg once weekly
• Weeks 13–16: 8 mg once weekly (if tolerated)
• Weeks 17–20: 10 mg once weekly (if tolerated)
• Week 21 onward: 12 mg once weekly (maintenance, if tolerated)

Dose escalation in the trials was subject to tolerability assessments — participants who experienced significant GI effects could pause escalation at the current dose (ClinicalTrials.gov — TRIUMPH-1, NCT05929066). The 8 mg and 12 mg doses represent the reported efficacy-optimized range in Phase 2 and Phase 3 respectively.

For research cost planning context, see the price-per-month guide in our Where to Buy Retatrutide comparison page.

How to reconstitute retatrutide (research use)#

Commercially available research-grade retatrutide is supplied as a lyophilized (freeze-dried) white powder in a sealed vial. In a laboratory setting, a lyophilized peptide must be reconstituted into solution before it can be analyzed or assayed.

This guide does not provide a reconstitution procedure, dilution figures, or storage durations. At a conceptual level, the principles that matter for any lyophilized peptide are well established: maintaining sterility during handling, keeping reconstituted material under appropriate cold storage, and protecting it from light all help preserve peptide integrity. The specific reagents, concentrations, volumes, handling steps, and storage limits appropriate to a given lot belong in a validated laboratory standard operating procedure (SOP) and the supplier's certificate of analysis — they are outside the scope of this article.

Under US federal law, retatrutide cannot be used in compounding and has not been found safe and effective for any condition (FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss). All handling discussed here is in a research-use-only context and is not instruction for human use.

Side effects and safety#

The following side effects are based on Phase 2 clinical trial data as reported in the published literature (Jastreboff et al., NEJM 2023). This is not a safety profile applicable to research use or personal administration — it is a summary of observed adverse events under controlled clinical conditions.

Gastrointestinal effects (most common)#

Consistent with the GLP-1 class, gastrointestinal adverse events were the most frequently reported side effects in Phase 2:

• Nausea — the most common adverse event, particularly during dose escalation. Reported at higher incidence in the highest-dose groups (Jastreboff et al., NEJM 2023).
• Vomiting — reported at meaningful incidence in the 8 mg group; less frequent in lower-dose groups (Jastreboff et al., NEJM 2023).
• Diarrhea — reported across dose groups; incidence generally correlated with dose level.
• Constipation — also reported, consistent with slowed gastric motility from GLP-1R agonism.
• Decreased appetite / early satiety — a functional effect that contributed to the weight-loss signal, also responsible for some nausea reports.

GI effects were most pronounced during the titration ramp and tended to attenuate after reaching a stable dose (Jastreboff et al., NEJM 2023). The phase 2 protocol used dose escalation specifically to manage this.

Dysesthesia (unique to retatrutide)#

A notable adverse event reported in Phase 2 that is not commonly observed with GLP-1 or GLP-1/GIP drugs is dysesthesia — abnormal skin sensations, described as tingling, burning, or numbness, typically in the extremities. Dysesthesia has been reported and may be related to retatrutide's pharmacology, but the mechanism is not fully established (Jastreboff et al., NEJM 2023). Incidence and severity data are in the published Phase 2 paper (Jastreboff et al., NEJM 2023). This is one of the distinguishing safety signals that differentiates retatrutide from tirzepatide.

Cardiovascular and metabolic monitoring signals#

Phase 2 data reported modest increases in heart rate at higher doses, consistent with the GLP-1 class (Jastreboff et al., NEJM 2023). Blood pressure reductions were also observed. Standard cardiovascular monitoring was part of the trial protocol.

Serious adverse events and discontinuations#

Serious adverse events and discontinuation rates at each dose level are reported in the Phase 2 publication (Jastreboff et al., NEJM 2023). Researchers accessing this compound for research purposes should read the full safety data in the primary literature before designing protocols.

YMYL note#

Retatrutide is an investigational compound with an incomplete long-term safety dataset. Phase 3 safety follow-up is ongoing. Any researcher or individual considering exposure to this compound should be aware that long-term safety data do not yet exist and that the FDA has not reviewed or approved it for any human use.

Retatrutide vs tirzepatide#

Tirzepatide (sold as Mounjaro for T2D and Zepbound for obesity) is the most relevant comparator — it is the only currently approved drug that targets both GLP-1R and GIPR, as retatrutide does, plus the additional glucagon receptor. Here is how they compare across key dimensions:

At-a-glance comparison:

These figures come from separate trials with different populations, endpoints, and durations — they are not a head-to-head comparison.

Mechanism

• Tirzepatide: dual agonist — GLP-1R + GIPR
• Retatrutide: triple agonist — GLP-1R + GIPR + GcgR

The glucagon receptor addition is the key mechanistic distinction. The GcgR arm drives thermogenic and hepatic fat-oxidation effects that tirzepatide does not produce.

Weight reduction signal (Phase 2 vs Phase 3 comparison)

• Tirzepatide Phase 3 (SURMOUNT-1): approximately 20–22% mean body weight reduction at 72 weeks at highest dose (15 mg) (Jastreboff et al., NEJM 2022)
• Retatrutide Phase 2: approximately 24.2% mean body weight reduction at 48 weeks at the highest dose (Jastreboff et al., NEJM 2023)
• Retatrutide Phase 3 (TRIUMPH-1 topline): up to 28.3% mean body weight reduction at 80 weeks (12 mg) (Eli Lilly, May 21 2026)

Direct head-to-head comparison data do not exist; these figures come from separate trials with different populations, endpoints, and durations. Retatrutide's Phase 3 topline now reinforces the larger weight-reduction signal seen in Phase 2, but only a head-to-head trial could establish a robust comparison against tirzepatide.

Side effect profiles

Both compounds produce GI adverse events (nausea, vomiting, diarrhea, constipation) consistent with GLP-1R agonism. Retatrutide uniquely adds dysesthesia as a reported adverse event, believed to stem from GcgR agonism. Tirzepatide has a more complete long-term safety dataset from Phase 3 trials and real-world post-approval use; retatrutide's long-term safety is not yet established.

Approval status

• Tirzepatide: FDA-approved (Mounjaro for T2D, 2022; Zepbound for obesity, 2023)
• Retatrutide: not FDA-approved; Phase 3 ongoing as of mid-2026

Availability

• Tirzepatide: available by prescription in the US (and from compounding pharmacies, with caveats)
• Retatrutide: available only from research chemical suppliers for research use, or via clinical trial enrollment

Research sourcing

If you need Tirzepatide for research alongside retatrutide, it is also tracked on our price comparison pages.

Retatrutide vs semaglutide#

Semaglutide (sold as Ozempic for T2D, Wegovy for obesity, Rybelsus oral) is the GLP-1 monotherapy benchmark.

Mechanism

• Semaglutide: GLP-1R agonist only
• Retatrutide: GLP-1R + GIPR + GcgR triple agonist

Semaglutide lacks both the GIPR component (which may improve tolerability) and the GcgR component (which drives thermogenic effects). This is the theoretical reason for the larger weight-loss signal observed with retatrutide and tirzepatide in trials.

Weight reduction (Phase 3 benchmarks)

• Semaglutide 2.4 mg (Wegovy, STEP-1 trial): approximately 15% mean body weight reduction at 68 weeks (Wilding et al., NEJM 2021)
• Retatrutide 8 mg (Phase 2, 48 weeks): approximately 24% (Jastreboff et al., NEJM 2023)

Again: different trials, different populations, different durations — not a direct head-to-head comparison.

Side effect profiles

Both produce GI adverse events via GLP-1R. Retatrutide adds dysesthesia (GcgR-related) and has a larger dose-escalation schedule. Semaglutide has the most complete long-term safety dataset of any GLP-1 drug (multiple years of post-approval real-world data). Retatrutide's long-term safety is unknown.

Approval status

• Semaglutide: FDA-approved for T2D (Ozempic) and obesity (Wegovy)
• Retatrutide: investigational only

Summary

Across the mechanistic and trial data available, retatrutide appears to represent a step beyond both semaglutide and tirzepatide in terms of weight-reduction magnitude — but with a less established safety record, no FDA approval, and only research-grade sourcing outside of trials. For researchers evaluating the comparative landscape, the relevant primary literature is the Phase 2 NEJM paper (Jastreboff et al., NEJM 2023) alongside the tirzepatide SURMOUNT and semaglutide STEP trial series.

FDA status and availability#

Current regulatory status#

Retatrutide is classified as an investigational new drug (IND) under FDA jurisdiction. It is not approved for any indication. The FDA has specifically warned against companies that sell compounded retatrutide or market it for human therapeutic use outside of authorized trials — including telehealth platforms and compounding pharmacies. The FDA's position is that unapproved retatrutide products pose unknown safety risks to patients (FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss).

Clinical trial availability (TRIUMPH program)#

Eli Lilly's TRIUMPH Phase 3 program is ongoing as of mid-2026. Active enrolling trials include TRIUMPH-1 (obesity, without T2D), TRIUMPH-2 (obesity, with T2D), and cardiovascular outcome trials. To find enrolling TRIUMPH trials, search ClinicalTrials.gov for "retatrutide" or "LY3437943." Trial participation is the only legal pathway to receive retatrutide as a therapeutic agent in the US.

Research use availability#

For non-clinical research purposes, retatrutide is available from the three vendors reviewed on our companion page. See our Where to Buy Retatrutide comparison for live pricing and vendor reviews.

When will retatrutide be available (approved)?#

Eli Lilly has not announced an NDA submission or target approval date as of mid-2026. Phase 3 trials are expected to conclude and report results within the next 1–2 years based on standard trial timelines, after which Lilly would need to submit and FDA would need to review an NDA. Conservative estimate: earliest possible approval would be 2027–2028, conditional on Phase 3 success and an accelerated review pathway — no approval is guaranteed.

FAQ

This article is for research and informational purposes only. [peptide:retatrutide] is an investigational compound not approved by the FDA for any therapeutic use. Nothing in this guide constitutes medical advice, dosing instructions, or an endorsement of personal use. Always consult a qualified healthcare professional before making any medical decisions.